Participants 542 587 3
MRI-defined locally advanced T3 resectable RC
Participants 592 758 3
arm A, patients received 12-week bevacizumab plus 5-FU, leucovorin and oxaliplatin (Folfox-4) followed with bevacizumab-5-FU-RT before total mesorectal excision (TME)
Participants 763 823 3
arm B, patients received only bevacizumab-5-FU-RT before TME
Participants 898 966 7
Forty-six patients were randomized in arm A and 45 patients in arm B
